Novartis (NYSE: NVS )
has done better over the past six months than I thought it would back
in December of 2013, as investors have liked what they've seen with the
company's restructuring efforts and surprisingly positive clinical data
on heart failure drug candidate LCZ696. In the "what have you done for
me lately?" world of Wall Street, though, I do wonder whether Novartis
has enough potential catalysts in hand to keep up a level of enthusiasm
that frankly seems outsized relative to the valuation.
Read more here:
Can Novartis AG Maintain Its Momentum?
No comments:
Post a Comment